Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 13 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma ESMO Calls for Cancer to Remain a Flagship Priority in the Next EU Budget MOST POPULAR How to Get Started With Meditation During Cancer June 21, 2022 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 Load more HOT NEWS Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining Does Living Near Power Lines Increase My Risk of Cancer? Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients...
